NT5E and glioblastoma: Overall, these data show the therapeutic efficacy of a localized dual-blockade of CD155 and CD73 within a synNotch activation cascade directly at the tumor-NK cell interface, and offer a new potential therapeutic strategy for treating GBM patients.